ReviewCancer science2016
Gene aberrations for precision medicine against lung adenocarcinoma.
Review in Cancer science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 143 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
143 citing papers in PubMed, 2 syntheses or guidelines pooled it, 242 citations in OpenAlex.
- Ethnic disparities in survival and progression among EGFR-mutated adenocarcinoma of lung cancer patients treated with tyrosine kinase inhibitors: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Pooled it
- Meta-analysis of mRNA expression profiles to identify differentially expressed genes in lung adenocarcinoma tissue from smokers and non-smokers.Oncology reports · 2018Pooled it
- Capmatinib in Japanese patients with MET exon 14 skipping-mutated or MET-amplified advanced NSCLC: GEOMETRY mono-1 study.Cancer science · 2021Trial
- Contrast-Enhanced Ultrasound Improves the Pathological Outcomes of US-Guided Core Needle Biopsy That Targets the Viable Area of Anterior Mediastinal Masses.BioMed research international · 2018Trial
- Development and Characterization of a Patient-DerivedJTO clinical and research reports · 2026Article
- Limited Immune-Mediated Efficacy of Anti-PD-L1/VEGF in EGFR-TKI-NaïveCurrent oncology (Toronto, Ont.) · 2026Article
- Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr-mutated lung cancer.Molecular oncology · 2026Article
- Successful Tepotinib Rechallenge after Tepotinib-induced Adverse Events Following Pembrolizumab Failure in a Case of Non-small Cell Lung Carcinoma with MET Exon 14 Skipping.Internal medicine (Tokyo, Japan) · 2026Article
- Prognostic Value of EGFR Mutation Subtypes After Linac-Based Stereotactic Radiosurgery or Fractionated Stereotactic Radiotherapy for Brain Metastasis From EGFR-Mutated Non-Small Cell Lung Cancer.Brain tumor research and treatment · 2026Article
- Differential Diagnosis of Solitary Pulmonary Nodules in Postoperative Pancreatic Cancer Patients Using KRAS Gene Mutation Analysis.Annals of surgical oncology · 2026Article
- Advancing Precision Medicine in Non-Small Cell Lung Cancer Diagnostics in a Southeast Asian Country.Cancer management and research · 2026Article
- Evaluation ofInternational journal of molecular sciences · 2025Article
- Comprehensive cancer analysis reveals CFH as an immune-related and prognostic marker.BMC cancer · 2025Article
- Epidemiologic and Survival Analyses of Lung Cancer in Nagano Prefecture: Impact of Serial Low-Dose Computed Tomography Screening.JTO clinical and research reports · 2025Article
- Investigating the role of oncogenic FAM83A as a prognostic biomarker in lung adenocarcinoma: Insights from smoker and non-smoker cohorts.Journal, genetic engineering & biotechnology · 2025Article
- A novel risk model incorporating 4 mitochondrial unfolded protein response-related genes to predict the prognosis, gene mutation landscape, and immunotherapy response in lung adenocarcinoma.European journal of medical research · 2025Article
- Review
- Prospective proteomics for discovering biomarkers in lung adenocarcinoma: a literature review.Translational cancer research · 2025Review
- Observational
- EMP3 is upregulated upon epithelial-mesenchymal transition and contributes to EGFR-tyrosine kinase inhibitor resistance in lung adenocarcinoma.European journal of medical research · 2025Article
83 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung adenocarcinoma (LADC), the most frequent histological type of lung cancer, is often triggered by an aberration in a driver oncogene in tumor cells. Examples of such aberrations are EGFR mutation and ALK fusion. Lung adenocarcinoma harboring such mutations can be treated with anticancer drugs that target the aberrant gene products. Additional oncogene aberrations, including RET, ROS1, and NRG1 fusions, skipping of exon 14 of MET, and mutations in BRAF, HER2, NF1, and MEK1, were recently added to the list of such "druggable" driver oncogene aberrations, and their responses to targeted therapies are currently being evaluated in clinical trials. However, approximately 30% and 50% of LADCs in patients in Japan and Europe/USA, respectively, lack the driver oncogene aberrations listed above. Therefore, novel therapeutic strategies, such as those that exploit the vulnerabilities of cancer cells with non-oncogene aberrations, are urgently required. This review summarizes the current status of research on precision medicine against LADC and enumerates the research priorities for the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.